Moderna and Merck report progress in cancer vaccine research. Moderna shifted focus toward cancer treatments, driving its stock up 177%. The company developed a custom mRNA treatment designed to combat skin cancer, though its effectiveness remains uncertain. Merck developed a cancer vaccine that could usher in a wave of similar treatments.
Opinions on the progress vary. Some people attribute success to market driven innovation, while others see it as an overdue advance. More research is needed to fully understand the implications of these findings. Nevertheless, the results show a hopeful path in cancer treatment.